Get the Stockscreener App
76.09
0.47%
0.295
Overview
News
Price History
Option Chain
Financials
Why ALC Down?
Discussions
Forecast
Dividend History
Alcon Inc stock is traded at $76.09, with a volume of 286.57K.
It is up +0.47% in the last 24 hours and up +3.85% over the past month.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
See More
Previous Close:
$75.80
Open:
$76.3
24h Volume:
286.57K
Relative Volume:
0.18
Market Cap:
$37.10B
Revenue:
$10.40B
Net Income/Loss:
$980.00M
P/E Ratio:
38.53
EPS:
1.9749
Net Cash Flow:
$1.61B
1W Performance:
-5.16%
1M Performance:
+3.85%
6M Performance:
+0.08%
1Y Performance:
-19.78%
1-Day Range:
$76.11
$76.75
1-Week Range:
$75.25
$80.28
52-Week Range:
$71.55
$99.20
Alcon Inc Stock (ALC) Company Profile
Name
Alcon Inc
Sector
Industry
Phone
-
Address
-
Compare ALC vs ISRG, BDX, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
76.12 | 36.95B | 10.40B | 980.00M | 1.61B | 1.9749 |
ISRG
Intuitive Surgical Inc
|
474.80 | 170.78B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
151.81 | 43.28B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
45.06 | 37.85B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
220.96 | 32.03B | 5.40B | 1.49B | 1.78B | 10.12 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-30-26 | Initiated | William Blair | Mkt Perform |
| Jan-20-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-09-26 | Downgrade | Stifel | Buy → Hold |
| Dec-11-25 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-21-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-20-25 | Downgrade | Deutsche Bank | Buy → Hold |
| May-14-25 | Reiterated | BTIG Research | Buy |
| Mar-28-25 | Reiterated | Needham | Buy |
| Mar-25-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-24-25 | Reiterated | Needham | Buy |
| Jan-10-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Dec-17-24 | Reiterated | Needham | Buy |
| Nov-12-24 | Reiterated | Needham | Buy |
| Oct-10-24 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Sep-10-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-15-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-15-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-10-24 | Initiated | Goldman | Buy |
| Mar-14-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Jan-23-24 | Initiated | Bernstein | Outperform |
| Dec-18-23 | Downgrade | Redburn Atlantic | Neutral → Sell |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-01-23 | Upgrade | Societe Generale | Sell → Hold |
| Dec-22-22 | Initiated | Mizuho | Buy |
| Nov-17-22 | Downgrade | Societe Generale | Hold → Sell |
| Aug-11-22 | Downgrade | Societe Generale | Buy → Hold |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| May-12-22 | Upgrade | Stephens | Equal-Weight → Overweight |
| Apr-08-22 | Initiated | Needham | Buy |
| Mar-11-22 | Initiated | BofA Securities | Buy |
| Jan-18-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-01-21 | Initiated | Oppenheimer | Perform |
| Jul-14-21 | Initiated | Deutsche Bank | Buy |
| May-06-21 | Upgrade | Citigroup | Sell → Neutral |
| Mar-22-21 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-12-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-06-20 | Downgrade | Citigroup | Neutral → Sell |
| Jul-06-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-08-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Argus | Hold → Buy |
| Mar-24-20 | Upgrade | Societe Generale | Sell → Hold |
| Mar-13-20 | Upgrade | UBS | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-26-20 | Upgrade | Berenberg | Hold → Buy |
| Jan-08-20 | Initiated | Argus | Hold |
| Oct-29-19 | Initiated | Stephens | Equal-Weight |
| Aug-21-19 | Reiterated | BofA/Merrill | Neutral |
| Jun-24-19 | Initiated | SVB Leerink | Mkt Perform |
| Jun-14-19 | Initiated | BTIG Research | Neutral |
| May-10-19 | Initiated | Robert W. Baird | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
View All
Alcon Inc Stock (ALC) Latest News
STAAR Surgical jumps after Alcon raises offer to $30.75/share in cash (update) - MSN
STAAR Surgical stock jumps 10% after Alcon sweetens buyout offer — investor says deal is 'worth substantially more' - MSN
STAAR Surgical sinks as it plans to terminate sale to Alcon (update) - MSN
STAAR Surgical's largest holder to vote against Alcon bid - MSN
Alcon slips as Q4 financial results miss on both lines - MSN
STAAR Surgical vote on Alcon may be delayed againReport - MSN
STAAR Surgical falls as proxy adviser recommends against revised Alcon deal (update) - MSN
Sight Sciences awarded $55.4 million in patent case against Alcon - Investing.com
Sight Sciences awarded $55.4 million in patent case against Alcon By Investing.com - Investing.com Australia
Alcon’s $186 Million South Fort Worth Bet Aims To Turbocharge Jobs - Hoodline
Alcon Inc stock (CH0432492467): Is vision care growth strong enough to unlock new upside? - AD HOC NEWS
Alcon Inc stock (CH0432492467): Is its eye care dominance strong enough to unlock new upside? - AD HOC NEWS
Alcon inks incentives deal for $186 million Fort Worth expansion - The Business Journals
Alcon Inc (ALC) Stock Down 3.1% -- Now Undervalued? GF Score: 80/100 - GuruFocus
Alcon Inc stock (CH0432492467): Why does its eye care dominance matter more for U.S. investors now? - AD HOC NEWS
RBC Capital Initiates Alcon(ALC.US) With Buy Rating, Announces Target Price $102.51 - Moomoo
How The Failed Alcon Deal Is Reframing The LENSAR (LNSR) Story And $10 Upside Potential - Yahoo Finance
Alcon Inc. stock (CH0432492467): Is its eye care dominance strong enough to unlock new upside? - AD HOC NEWS
Alcon Inc stock (CH0432492467): Is its eye care dominance strong enough to unlock steady growth? - AD HOC NEWS
Alcon Inc stock (CH0432492467): Is its eye care dominance strong enough for sustained U.S. investor - AD HOC NEWS
National Advertising Division Finds Certain ACUVUE® Oasys Max Claim Supported; Recommends Modification or Discontinuation of Others - The Manila Times
National Advertising Division Finds Certain ACUVUE® Oasys Max Claim Supported; Recommends Modification or Discontinuation of Others - GlobeNewswire Inc.
On the Record: Alcon invests $60M in Cabell County facility - MSN
Alcon Inc. (ALC) Stock Analysis: A 16.43% Potential Upside In The Healthcare Sector - DirectorsTalk Interviews
Alcon Inc stock (CH0432492467): Is its eye care dominance strong enough for steady investor gains? - AD HOC NEWS
Alcon Inc. stock (CH0432492467): Is vision care dominance strong enough to unlock steady growth for - AD HOC NEWS
Alcon Inc stock (CH0432492467): Is its eye care dominance strong enough to unlock steady upside? - AD HOC NEWS
Systane Augentropfen: Eye Relief Demand Surges Amid Screen Time Boom - AD HOC NEWS
Systane Augentropfen: Dry Eye Relief Gains Traction Amid Screen Time Surge - AD HOC NEWS
Alcon Inc stock (CH0432492467): Is its eye care dominance strong enough for steady U.S. investor ret - AD HOC NEWS
Alcon Inc stock (CH0432492467): Why Google Discover changes matter more now - AD HOC NEWS
Sight Sciences wins $34M patent ruling against Alcon - MSN
Systane Augentropfen: Eye Health Demand Surges Amid Screen Time Boom - AD HOC NEWS
Optician OnlineWCO & Alcon release interactive DED toolOptician Online - Trucknet UK
Bernstein SocGen reiterates Alcon stock rating on dry eye outlook - Investing.com UK
Bernstein SocGen reiterates Alcon stock rating on dry eye outlook By Investing.com - Investing.com Australia
Alcon Inc. stock (CH0432492467): Why does its eye care dominance matter more for U.S. investors now? - AD HOC NEWS
Alcon Inc stock (CH0432492467): Is vision care demand strong enough to sustain long-term growth? - AD HOC NEWS
Are Medical Stocks Lagging Alcon (ALC) This Year? - Yahoo Finance
Alcon Announces U.S. Launch of Clareon TruPlus IOLs - VisionMonday.com
Systane Augentropfen: Eye Health Boom Puts Alcon's Dry Eye Leader in Focus - AD HOC NEWS
Alcon Inc stock (CH0432492467): Is vision care dominance strong enough to unlock new upside? - AD HOC NEWS
Alcon Inc stock (CH0432492467): Is vision care's steady growth strong enough to unlock new upside? - AD HOC NEWS
Analysis Recap: Will Alcon Inc benefit from rate cutsEarnings Miss & Weekly High Momentum Picks - baoquankhu1.vn
Alcon launches Clareon TruPlus monofocal and toric IOL - Eyes On Eyecare
Alcon Inc stock: What you need to know before investing now - AD HOC NEWS
Assessing Alcon (SWX:ALC) Valuation After Clareon TruPlus Lens Launch At ASCRS Meeting - Yahoo Finance
Is It Time To Reconsider Alcon (SWX:ALC) After Its 15.5% One Year Share Price Decline - Yahoo Finance
Alcon Inc Stock (ALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):